Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2017 Results

SAN DIEGO, July 28, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report second quarter 2017 results after the Nasdaq market close on August 3, 2017.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update that day at 5:00pm Eastern Time (2:00pm Pacific Time).

Participants can access the live conference call by dialing 888-632-3381 (US) or 785-424-1678 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement, please contact the Investor Relations Department at ir@neurocrine.com. A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-243-8160 (US) or 402-220-9032 (International) using the conference ID: NBIX. The call will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. In April of 2017, the FDA approved INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).  INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first and only FDA-approved product indicated for the treatment of adults with TD.  The Company markets INGREZZA in the United States. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA (valbenazine), a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

View original content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-second-quarter-2017-results-300495827.html

SOURCE Neurocrine Biosciences, Inc.